Medindia

X

Access Pharmaceuticals Cobraxane Program Displays Significant Advantage Over Commercially-Available Paclitaxel Protein-Bound Particles

Wednesday, May 11, 2011 General News J E 4
Advertisement
Comparative Studies From Company's CobaCyte Tumor-Targeting Technology Program, Cobraxane, Demonstrate Superior Tumor Growth Inhibition

Contact: Company

Contact: Investor Relations

Christine Berni

Donald C. Weinberger/Diana Bittner (media)

Director of Investor Relations

Wolfe Axelrod Weinberger Assoc. LLC

Access Pharmaceuticals, Inc.

(212) 370-4500

(212) 786-6208

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Your Dysfunctional Nonprofit Board - What to Do
S
Vermillion Reports Financial Results for the First...